Na+/K+-ATPase is present in scrapie-associated fibrils, modulates PrP misfolding In vitro and links PrP function and dysfunction by Graham, James F. et al.
Na+/K+-ATPase Is Present in Scrapie-Associated Fibrils,
Modulates PrP Misfolding In Vitro and Links PrP Function
and Dysfunction
James F. Graham1, Dominic Kurian2, Sonya Agarwal1, Lorna Toovey1, Lawrence Hunt2, Louise Kirby1,
Teresa J. T. Pinheiro3, Steven J. Banner1, Andrew C. Gill1*
1 The Roslin Institute and R(D)SVS, Neuropathogenesis Division, University of Edinburgh, Easter Bush, Roslin, Edinburgh, Midlothian, United Kingdom, 2 Institute for
Animal Health, Compton, Newbury, Berkshire, United Kingdom, 3 School of Biological Sciences, University of Warwick, Coventry, United Kingdom
Abstract
Transmissible spongiform encephalopathies are characterised by widespread deposition of fibrillar and/or plaque-like forms
of the prion protein. These aggregated forms are produced by misfolding of the normal prion protein, PrPC, to the disease-
associated form, PrPSc, through mechanisms that remain elusive but which require either direct or indirect interaction
between PrPC and PrPSc isoforms. A wealth of evidence implicates other non-PrP molecules as active participants in the
misfolding process, to catalyse and direct the conformational conversion of PrPC or to provide a scaffold ensuring correct
alignment of PrPC and PrPSc during conversion. Such molecules may be specific to different scrapie strains to facilitate
differential prion protein misfolding. Since molecular cofactors may become integrated into the growing protein fibril
during prion conversion, we have investigated the proteins contained in prion disease-specific deposits by shotgun
proteomics of scrapie-associated fibrils (SAF) from mice infected with 3 different strains of mouse-passaged scrapie.
Concomitant use of negative control preparations allowed us to identify and discount proteins that are enriched non-
specifically by the SAF isolation protocol. We found several proteins that co-purified specifically with SAF from infected
brains but none of these were reproducibly and demonstrably specific for particular scrapie strains. The a-chain of Na+/K+-
ATPase was common to SAF from all 3 strains and we tested the ability of this protein to modulate in vitro misfolding of
recombinant PrP. Na+/K+-ATPase enhanced the efficiency of disease-specific conversion of recombinant PrP suggesting that
it may act as a molecular cofactor. Consistent with previous results, the same protein inhibited fibrillisation kinetics of
recombinant PrP. Since functional interactions between PrPC and Na+/K+-ATPase have previously been reported in
astrocytes, our data highlight this molecule as a key link between PrP function, dysfunction and misfolding.
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Introduction
Transmissible spongiform encephalopathies (TSEs) are a group
of fatal neurodegenerative disorders affecting humans and
animals. TSEs are characterised by the post-translational conver-
sion of the host prion protein, PrPC, to a disease-associated
isoform, PrPSc. PrPC is largely a-helical in structure, whilst PrPSc
possesses dramatically increased levels of b-sheet; it is also partially
protease resistant and accumulates in insoluble plaques and fibrils
during disease. PrPSc is hypothesised to be the principle
component of the TSE infectious agent but the molecular basis
of the process by which PrPC is converted to PrPSc is still unknown
[1]. It is assumed that PrPSc acts catalytically by imposing its
conformation onto nascent PrPC causing the disease-associated
structural changes. In this case, the information required to
passage disease is believed to be encoded in the tertiary or
quaternary structure of PrPSc [2]. A major challenge to this
hypothesis is the existence of many different TSE strains that can
be passaged, with high fidelity, in congenic hosts. This requires
PrPSc to exist in many different stable isoforms, each capable of
passing sufficient information to cause the differing pathology
resulting from specific strains of disease [2,3]. Accumulating
evidence suggests that interactions between PrPC/PrPSc and
molecular cofactors are necessary for the conversion process to
take place [4]. Such molecules could act directly, as chaperones to
assist in the misfolding of PrPC, or could act indirectly through the
formation of a molecular scaffold [5] that allows for the correct
spatial alignment between PrPC and PrPSc. Alternatively,
accessory molecules may modulate PrPC structure to ensure the
correct folded form is available for conversion [6]. Many accessory
molecules may exist in vivo and their involvement in prion protein
misfolding may differ depending on TSE strain [7]. Defining the
identity of molecular cofactors that aid prion misfolding in vivo is a
key goal in TSE research.
In order for accessory molecules to be part of the conversion
process they must come into contact with either PrPC or PrPSc.
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Cofactors may, therefore, be molecules with which the prion
protein interacts during normal cell biology. Based on published
studies, a range of candidates exists [8,9,10] and particular
examples include neural cell adhesion molecule (N-CAM) [11] and
the 37/67 kDa Laminin receptor [12]. PrPC has also been
reported to bind to copper ions [13], nucleic acids [14], lipids [15]
and glycosaminoglycans [16]. In cell culture, pro-low density
lipoprotein receptor 1 (LRP-1) [17] and glypican-1 [18] have
recently been suggested to mediate PrP misfolding. In short, a
range of different molecules covering almost all biomolecular
subsets are candidates for prion conversion cofactors. However,
Deleault et al. [19] published work demonstrating that misfolding
of the prion protein into an infectious isoform in vitro could be
achieved using only poly(A)RNA and molecules, including lipidic
components, that co-purified with PrPC. Wang et al have also
shown that recombinant PrP (recPrP), expressed by a prokaryotic
system, can be induced to misfold into infectious isoforms in the
presence of lipid and nucleic acid, strengthening the case for these
molecules as bona fide prion protein conversion cofactors [20]. Both
pieces of work, however, made use of misfolding assay conditions
with periodic sonication, which may impart sufficient energy to
overcome the conversion threshold that would normally be
facilitated by cofactors in vivo [21]. Furthermore, recent results
suggest that nucleic acid may not aid conversion in all mammalian
systems and, in some species, cofactors may be localised to the
plasma membrane of cells [22]. Together these observations
demonstrate that the identities of the molecular species aiding
prion conversion, particularly those molecules playing this role in
vivo, are still largely unknown.
Accessory molecules that facilitate prion protein misfolding may
become integrated into the growing protein fibril. Several
researchers have reported the identification of proteins enriched
in TSE-specific fibrils but have either used no negative control
preparations [23,24], or have used proteinase K (PK) in the
purification procedure [25]. The PK step retains the protease-
resistant core of PrPSc but may result in digestion of cofactors that
are bound loosely in the fibril and are accessible to proteases. Even
partial PK digestion of such proteins will hinder MS-based protein
identification.
We have isolated scrapie-associated fibrils (SAF) from mouse
brains by means of crude preparation procedures in the absence of
protease treatment and have adopted a shotgun proteomics
approach to the identification of proteins that co-purify with the
SAF. SAF preparations were made from the brains of mice
infected with 3 different strains of mouse-passaged scrapie, ME7,
79A and 22F. As controls, we also made equivalent preparations
from uninfected wildtype mouse brains (WT) and from mice in
which the Prnp gene has been knocked out (PrP2/2). We found
several proteins in control preparations that have previously been
reported [23,24] to be integral to SAF. Additionally, several
molecules were identified that appear specifically associated with
SAF, including the a-chain of sodium/potassium transporting
ATPase (Na+/K+-ATPase) and an isoform of the guanine
nucleotide binding protein, but there was limited evidence for
proteinaceous cofactors segregating specifically and reproducibly
with SAF from any one of the TSE strains used. By use of two
established in vitro misfolding assays, we found that Na+/K+-
ATPase modulates the misfolding of recPrP, suggesting that it may
act as a non-strain specific catalyst in prion misfolding in vivo.
Coupled with reports of functional associations between PrPC and
Na+/K+-ATPase in cultures of astrocyte s [26], our novel findings
provide a key molecular link between PrP function and misfolding
and suggest that neurotoxicity associated with prion diseases may
involve both loss and gain of function.
Results and Discussion
Multiple proteinaceous species copurify with PrPSc in SAF
from three different mouse strains
In our laboratory, routinely we use a method for the
preparation of scrapie associated fibrils from TSE-infected brain
homogenate that was developed over two decades ago [27]. The
procedure is relatively crude and involves tissue homogenisation
followed by detergent extraction and differential centrifugation to
enrich for detergent insoluble, aggregated species. Further
extraction and processing is possible from this stage to produce
preparations that retain TSE infectivity, but such processes often
involve the use of harsh solvent conditions or protease treatment to
remove PK-sensitive proteins [28]. Although clearly allowing
enhanced purification of PrPSc, these procedures may also remove
cofactors that were important in vivo during the misfolding process.
Such cofactors may be loosely associated with SAF and susceptible
to protease treatment and we wanted to retain these proteins since
they may be relevant to the misfolding process. Hence, for all
analyses, SAF preparations were used directly without further
processing.
SAF were purified from the brains of mice terminally affected
with the mouse-passaged scrapie strains ME7, 79A and 22F. After
purification, SAF-specific proteins were separated by SDS-PAGE
and the gels were either blotted to PVDF and the membrane
probed with the anti-PrP antibody 8H4, or proteins were
visualised by silver staining. Representative Western blots are
shown in Figure 1(a)–(c), with and without proteinase K treatment.
For each Western blot we loaded a nominal amount of 0.1 mg of
SAF onto SDS-PAGE gels based on the estimate that 10 mg of
SAF can be extracted from a single mouse brain. Prior to PK
digestion, PrP resolves as a mixture of isoforms depending on the
presence or absence of the two N-linked carbohydrates and the N-
terminal region. After PK digestion, for all three strains PrP-
immunoreactive bands separated into characteristic triplets
between 17–27 kDa associated with the three different glycoforms
of PrP: un-, mono- and di-glycosylated. Significant work has
shown that ratios of the prevalence of each glycoform can be used
as a diagnostic marker for different strains of TSE disease, at least
when the total PrPSc from a brain sample is analysed [29]. The
intensities of bands on our Western blots are comparable with
glycoform ratios previously published [30], demonstrating the
TSE strain-specific nature of the SAF preparations. The
densitometric intensities of Western Blot bands were compared
to a range of standards produced by Western blotting recPrP at
different concentrations (not shown). This allowed us to estimate
the actual amount of PrPSc present in each SAF preparation and
allowed the standardisation of subsequent analyses for PrPSc
content.
We used SDS-PAGE to attempt to determine the approximate
number of proteins co-purifying alongside PrPSc in each strain
and whether differences could be detected in the protein profile
of SAF preparations from different mouse-passaged scrapie
strains. Figure 1(d) shows a representative silver stained gel of
SAF preparations at two different dilutions, as determined by
Western blotting, and both with and without PK treatment. Prior
to PK digestion, SAF from each strain contains a range of non-
PrP proteins, as evidenced by a variety of discrete bands and
poorly resolved smears on the gel (Figure 1(d)). A particularly
intense band is evident around 45 kDa and is present in SAF
preparations from all 3 strains. After PK digestion of SAF from
each strain, there are also poorly resolved signals on the gel
although most appear in the low mass region. The intense band
at ,30 kDa in PK positive lanes represents PK. Since SAF are
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poorly soluble and aggregated, the quality of SDS-PAGE
separations cannot readily be improved and from our gels it
was problematic to compare protein species present in SAF from
different strains; in non-PK treated lanes, the proteins are too
numerous to quantify and many of the bands are too diffuse to
allow individual protein species to be identified or to allow either
qualitative or quantitative comparisons between strains. Howev-
er, the reduced number of protein signals after PK digestion
justifies the use of purification methods that do not employ
protease treatment to analyse SAF-associated proteins. To
identify SAF-associated proteins, we adopted the method of
shotgun proteomics [31], a technique that avoids SDS-PAGE
analysis and that allows the analysis of proteins directly from in-
solution tryptic digests.
Control preparations contain proteins previously
suggested to be integral to SAF
The SAF preparation protocol is believed to result primarily in
the enrichment of amyloid fibrils. However, since our procedure is
relatively crude and does not use a protease step, there will
inevitably be contamination from other proteins that are not
incorporated into SAF in vivo, but which share similar biochemical
properties, such as insolubility and/or high molecular weight. In
the absence of PK treatment or quantitative comparisons of SDS-
PAGE protein profiles, there is no proteomic-based method to
discriminate those proteins that are present in SAF preparations
non-specifically from those that are genuinely SAF-associated. To
allow us to identify and discard non-specifically co-purifying
proteins from shotgun proteomic analyses, the SAF purification
Figure 1. SAF preparations contain protease resistant PrP and a range of other proteins. Panels (A), (B) and (C) show representative
results of Western blotting of SAF preparations from mice infected with ME7, 22F and 79A scrapie respectively, both with and without PK digestion.
Blots were probed with the anti-PrP antibody 8H4. Quantities stated are estimates of the amount of PrPSc based on a yield of 10 mg PrPSc per brain.
Panel (D) shows a silver stained SDS-PAGE gel of different SAF preparations. Two different dilutions were loaded for each SAF preparation, both with
and without PK digestion. Quantities stated relate to PrPSc amounts loaded after balancing based on semi-quantitative Western blotting. Molecular
weight markers are in kDa.
doi:10.1371/journal.pone.0026813.g001
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protocol was applied to uninfected WT and PrP2/2 mouse brains
to generate control preparations. These preparations were applied
to our proteomics workflow to produce a list of proteins that could
be excluded from subsequent analysis of PrPSc-containing SAF
preparations.
After reduction, alkylation and tryptic digestion under denaturing
conditions, online nanoLC-MS/MS of control preparations from
uninfected WT mouse brains allowed the identification of several
purified proteins. The identities of these proteins are reported in
Table 1 and were assessed to be significant if there were a minimum
of two peptides identified by LC-MS/MS with protein-level Mascot
scores above the confidence threshold. Four proteins were identified
in preparations from normal mouse brains: three different chains of
calcium/calmodulin dependent kinase (CamKII) and a ferritin
isoform. A control preparation from PrP2/2 mice had a vastly
reduced number of identified peptides and the only significant hit
was to CamKII a-chain. Other proteins were identified in SAF
preparations from wildtype mice (see Supplementary Mascot
Searches S1), but were below the level of confidence or had only
a single peptide identified, hence are not reported here.
Since the SAF purification procedure enriches for proteins that
are high molecular weight and detergent insoluble, it is not
surprising that CamKII and ferritin were present in control
preparations. The native proteins exist as multimers of high
molecular weight (500–600 kDa, and 450 kDa respectively) and
ferritin is known to oligomerise, which will cause further increases
in molecular weight [32]. Ferritin has previously been shown to
contaminate SAF preparations [33] whilst CamKII, a serine/
threonine protein kinase located in synaptic junctions, is highly
abundant in brain and one may expect at least a proportion of the
protein to be present within the detergent-insoluble fractions.
Previous proteomic studies of SAF have identified CamKII and
ferritin as co-purifying with TSE-specific SAF preparations. These
studies, however, did not include shotgun MS analyses of control
preparations [23,24], although a more recent study by Moore et al,
which did include this type of experiment, also identified these two
proteins in control preparations [25]. Thus, our data reinforces the
notion that these proteins are non-specific contaminants of SAF
preparations and are not associated with PrPSc. As a result of
additional processing steps resulting in increased protein concen-
trations, Moore et al. also found additional proteins present in
control preparations, including ribosomal and proteasomal
subunits, versican core protein and myelin associated proteins.
Our experiments, in conjunction with those of Moore et al.,
provide a background list of proteins that appear to co-purify to
the same fractions as SAF using the isolation techniques described,
even in the absence of TSE disease in mice. This allows any
identification of these proteins in analyses of SAF preparations
from infected mice to be interpreted with care. We cannot rule out
that proteins identified in control preparations may also associate
with PrPSc and therefore become more highly enriched in
preparations when comparing TSE-infected verses non-infected
mouse brains. To prove this would necessitate carefully controlled
quantitative proteomic work.
Mass spectrometry of infected SAF preparations confirms
the presence of specific proteins in addition to PrPSc
To identify proteins that associate with PrPSc, particularly those
that may be strain specific, replicate SAF preparations were
generated from the brains of mice inoculated with ME7, 22F and
79A scrapie. After reduction, alkylation and tryptic digestion,
peptides were analysed by online LC-MS/MS and the resulting
MS/MS spectra were submitted to Mascot for searching against
the IPI mouse database. As previously, proteins were discounted if
they had only a single peptide hit associated with them or if they
were below the significance threshold determined by the Mascot
algorithm. We used a confidence limit of 99% and this yielded
peptide-level false-positive discovery rates that were all less than
2.5% and typically 0%. A compiled list of proteins identified by
the above criteria is shown in Table 2, but full Mascot search
results are also provided as Supplementary Mascot Searches S1.
Some proteins identified in our experiments had previously been
identified in the uninfected control preparations, including various
chains of the CamKII protein and both light and heavy chains of
ferritin. Additionally, some proteins detected in mock SAF
preparations by Moore et al [25] were also identified in our
infected SAF preparations and include various actin isoforms,
versican core protein and myelin-associated oligodendrocyte basic
protein. These proteins are not included in table 2 but a full,
compiled list of proteomic identifications is available (Table S1).
We detected over 20 individual proteins in our SAF preparations.
The prion protein was detected in 5/6 preparations, although was
not detected in one of the replicate samples from 22F infected
brains. The reason for this is not clear, but we noticed that over
several repeat preparations of 22F fibrils, there was a reduction in
protein yield and it is conceivable that trace levels of specific
proteases co-purified with SAF from this strain and caused excessive
proteolysis of the sample. Addition of protease inhibitors during
SAF preparation is not compatible with subsequent tryptic digestion
and MS analysis, hence we were unable to avoid excessive
proteolysis. Furthermore, we also note that tryptic digestion of
PrP yields only a handful of peptides that are immediately amenable
to LC-MS/MS analysis and sequence coverage of PrP is limited at
best. Against the limited detection efficacy of PrP byMS techniques,
Table 1. LC-MS/MS identification of proteins associated with the mock-SAF preparations of uninfected mouse brains.
Gene and protein name
WT Mascot score
(Peptide matches)
PrP2/2 Mascot score
(Peptide matches)
CamK2a Calcium/calmodulin dependent kinase type II a-chain 1043 (8) 276 (4)
CamK2b Calcium/calmodulin dependent kinase type II b-chain 313 (10) -
Camk2d Calcium/calmodulin dependent kinase type II d-chain 198 (5) -
Ftl1 Ferritin (light chain 1) 71 (2) -
The SAF preparation procedure was carried out on both uninfected wildtype mouse brains (WT) or uninfected knockout mouse brains (PrP2/2). Four brains for each
mouse strain were homogenised prior to detergent extraction and differential centrifugation to isolate protein species. Precipitated proteins were reduced and
alkylated in 6 M guanidine hydrochloride then digested with typsin. Tryptic peptides were separated and detected by online LC-MS/MS and the data searched against
the IPI murine database by use of the Mascot search algorithm. Proteins that were below the level of significance or for which only single peptides were identified are
not reported.
doi:10.1371/journal.pone.0026813.t001
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any reduction in yield of tryptic peptides during proteomic
workflows would dramatically inhibit detection of prion protein.
The proteins with the highest Mascot scores were either chains
of the CamKII protein, isoforms of b-tubulin or isoforms of actin.
Tubulin is an integral component of microtubules – polymeric,
high molecular weight assemblies that form part of the
cytoskeleton and are abundant in the brain. As a result, tubulin
isoforms may have been expected to occur in control preparations,
since the generic nature of the techniques used will necessarily
select for molecules with the same physical characteristics of PrPSc.
However, tubulin isoforms were not identified conclusively in
control preparations and this strengthens the evidence for their
specific association with PrPSc in fibrillar deposits. The sequence
similarity between different b-tubulin isoforms is high and it was
not possible unambiguously to determine the predominate
isoform. Interestingly, different tubulin isoforms have been found
to be associated with inclusions formed during other protein
misfolding diseases [34,35,36,37] and microtubules may function
as a scaffold to bring together normally folded proteins with a
growing nucleus of misfolded protein. Alternatively, protein
aggregates may associate with microtubles and other cytoskeletal
structures after the aggregates have formed, as a mechanism by
which the cell localises misfolded protein. It is noteworthy that
many protein misfolding diseases are characterised by deregula-
tion of tubulin polymerisation, potentially suggesting a key role for
cytoskeletal components in neurodegeneration. However, we also
cannot rule out that a non-physiological association occurs
between tubulin and PrPSc, during the SAF isolation procedure.
In addition to cytoskeletal proteins, several plasma membrane
bound proteins were also identified as present in SAF preparations
Table 2. Proteins present in scrapie associated fibrils from ME7, 79A and 22F mouse-passaged scrapie.
TSE strain (code for supporting data) ME7 (10881) ME7 (10754)c 22F (10882) 22F (10753)c 79A (10883) 79A (10755)c
Gene and Protein Name
Mascot Score
(peptide
matches)
Mascot Score
(peptide
matches)
Mascot Score
(peptide
matches)
Mascot Score
(peptide
matches)
Mascot Score
(peptide
matches)
Mascot Score
(peptide
matches)
Tubb# Tubulin b-chains, variousa Max 259 (7) Max 392 (11) Max 415 (6) Max 504 (8) Max 246 (6) Max 656 (12)
Gnao1 Isoform Alpha-2 of Guanine
nucleotide-binding protein
G(o) subunit alphaa
227 (3) 278 (4) 70 (3) 212 (3) 208 (2) 367 (7)
Apoe Apolipoprotein E 226 (9) 92 (6) nd nd 147 (5) 67 (4)
Atp1a3 Na+/K+ ATPase subunits a3/a2a 171 (3) 312 (5) 198 (4) 130 (3) dbcl 397 (8)
Prnp Major prion protein 168 (4) 236 (5) 41 (2) nd 70 (3) 282 (5)
Srrm2 Serine arginine repetitive
matrix protein 2
134 (4) nd nd nd nd nd
H1f0 Histone H1.0 102 (3) nd nd 53 (2) nd nd
Hspa8 Heat shock cognate 71 kDa protein 79 (3) 52 (2) nd nd nd 136 (6)
Tbc1d10b TBC1 domain family,
member 10b
76 (2) nd nd nd nd nd
Nsf Vesicle-fusing ATPase 67 (2) 37 (2) nd nd nd dbcl
Ckb Creatine kinase B-type 56 (3) 341 (5) 160 (3) dbcl dbcl 170 (5)
Lrp1 Pro low-density lipoprotein
receptor-related protein 1
37 (2) nd nd nd 88 (3) 170 (3)
Tuba# Tubulin a-chains, variousa nd 246 (6) 288 (3) 341 (6) nd Max 427 (9)
LOC100039214; similar to
Glyceraldehyde-3-phosphate
dehydrogenase isoform 1
dbcl 186 (3) 78 (3) 99 (2) dbcl 250 (7)
Dlg4 Isoform 2 of Disks large homolog 4 nd nd 65 (2) nd dbcl nd
Ubb;Ubiquitin dbcl dbcl dbcl 171 (2) nd 158 (3)
Cnp Isoform CNPII of
29,39-cyclic-nucleotide 39-phosphodiesterase
nd nd nd nd dbcl 159 (3)
Syn1 Isoform Ib/Syn2 isoform
IIb of Synapsin1
nd nd nd nd nd 94 (4)/47 (2)
Dnm1 Isoform 1 of Dynamin 1 nd nd nd nd nd 66 (2)
Eno1 Alpha Enolase nd nd nd nd nd 60 (2)
SAF were purified from the brains of mice infected with ME7, 22F or 79A strains of mouse-passaged scrapie. Duplicate preparations were made and the 6 samples were
reduced and alkylated in 6 M guanidine hydrochloride prior to tryptic digestion. Tryptic peptides were separated and detected by online LC-MS/MS and the data
searched against the IPI murine database by use of the Mascot search algorithm. Proteins are listed in the table if they were identified conclusively in at least one SAF
preparation. Protein hits were deemed to be conclusively identified if they were above the level of significance (as determined by Mascot scores) and more than one
peptide matched to the sequence. Proteins identified in these experiments but that had previously been identified in control preparations from uninfected brains are
not listed in this table, but full compiled results are available (Table S1). nd – not detected. dbcl – protein detected but below the level of confidence because only a
single peptide was matched.
a– due to extensive sequence homology between different chains of these proteins it is not possible to tell whether only a single isoform or multiple isoforms are
present.
doi:10.1371/journal.pone.0026813.t002
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from multiple scrapie strains. Proteins such as the a-chain of Na+/
K+-ATPase (note that peptides matched to both a2- and a3-
chains) and the GO G-protein Gnao1 were detected in almost all
SAF preparations, suggesting that they are not strain specific
cofactors. Nevertheless, the plasma membrane has been hypothe-
sised to be the site of prion conversion based on evidence derived
from cell culture models [38] whilst recent data from our
laboratory [39] and also that of others [22,40], has indicated that
plasma membrane preparations may contain factors that enhance
conversion of PrP. The presence of plasma membrane specific
proteins in our SAF preparations could, therefore, point to the
cellular location of conversion. These proteins may be involved in
normal PrPC function, in misfolding or may simply be located
proximal to the misfolding PrPC molecule. As such, they may
become integrated into the fibril in either active or passive
processes. In addition to Na+/K+-ATPase and Gnao1, other
plasma membrane associated proteins that were detected in SAF
included apolipoprotein E (ApoE), isoform 2 of disks large
homolog 4 and LRP-1, which has previously been suggested to
play a role in PrPC trafficking [17,41].
The remainder of proteins detected in multiple SAF prepara-
tions were predominately cytoplasmic and included creatine kinase
B, which was detected in preparations of SAF from all three strains
and which has previously been shown to bind PrPC [42], a
GAPDH-like protein, a histone isoform as well as heat shock
cognate 71 kDa protein and a protein with homology to ubiquitin.
These latter two proteins are part of the unfolded protein response
and they have been found to be associated with inclusions in other
protein misfolding diseases. In single SAF preparations we also
detected the TBC1 domain family member 10b, the vesicle fusing
ATPase, Nsf, the serine-arginine repetitive matrix protein 2
(srrm2), CNPII, synapsin-1 and dynamin 1, amongst others. None
of the proteins that we identified were present specifically and
reproducibly in repeat SAF preparations from a single TSE strain
suggesting that if strain specific cofactors exist they are non-
proteinaceous, do not get integrated into the amyloid deposits or
are present only in quantities too small to allow detection.
Western blotting validates the presence of ApoE and
Na+/K+-ATPase in SAF preparations
In order to validate our proteomics studies, we selected two
biologically interesting proteins for follow up studies, ApoE and
Na+/K+-ATPase. Our decision was based on established links of
both proteins to other neurodegenerative disorders in addition to
the availability of antibodies. We have demonstrated by Western
blotting that the SAF preparations from infected tissues contained
protease-resistant PrP (Figure 1(a–c)) and we additionally per-
formed Western blotting using an antibody against ApoE and
several different antibodies that recognise various different a-
chains of Na+/K+-ATPase. Representative Western blots for
ApoE and Na+/K+-ATPase are shown in Figure 2(a–d). In each
case we balanced the loading of SAF preparations based on semi-
quantitative measures of PrPSc levels. We also included lanes
containing our negative control preparations. As shown in
Figure 2(a), immunoreactivity for ApoE was present as a discrete
band at ,36 kDa in all three lanes corresponding to infected SAF
preparations, but not in the two mock SAF preparations from
uninfected WT and PrP2/2 mice. The signal in the 22F SAF
preparation was weak compared with ME7 and 79A preparations,
but clearly present on longer exposure (data not shown). Western
blotting using a pan a-chain polyclonal antibody demonstrated the
presence of the Na+/K+-ATPase a-chain in all three SAF
preparations from infected mice, but not in the two control
preparations. Immunoreactivity was present as a single band at
,100 kDa, consistent with previous reports and with the
calculated molecular mass of Na+/K+-ATPase a-chains of
,100–110 kDa. Since we could not distinguish whether a2- or
a3-chains were selectively present from our proteomics results, we
also probed blots with antibodies that specifically recognised a2- or
a3-chains and typical results are shown in Figure 2(c) and (d)
respectively. These data show clearly that both a2- and a3-chains
are present in preparations of SAF from infected mouse brains, but
not in control preparations. Combined, the results of our Western
blots confirm the presence of three potentially interesting proteins
in infected SAF preparations and validate our proteomics data.
Na+/K+-ATPase enhances cell free conversion of murine
recombinant PrP and acts as a potential conversion
cofactor
Both a2- and a3-subunits of Na+/K+-ATPase were detected
specifically in SAF preparations, by Western blotting. In brain, the
a2-chain is expressed predominately in glia whilst the a3-chain is
Figure 2. Western blotting confirms the presence of ApoE and
Na+/K+-ATPase a-chains in SAF preparations. Based on an
estimate of 10 mg PrPSc per brain, the equivalent of 0.25 mg/ml PrPSc
from an ME7 (lane 1), 22F (lane 2) and 79A (lane 3) SAF preparation
were resolved by SDS-PAGE, blotted onto PVDF membrane and probed
with the primary antibody against (A) Apolipoprotein E (B) Total Na+/K+
ATPase a-chains using a pan a-chain antibody (C) Na+/K+ ATPase a2
isoform and (D) Na+/K+ ATPase a3 isoform. In all cases, in lanes 4 and 5
were loaded the equivalent of 0.25 mg/ml of control preparation
material from uninfected WT and PrP2/2 mouse brains respectively.
Molecular weight markers are in kDa.
doi:10.1371/journal.pone.0026813.g002
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more highly enriched in neurons, however single subunits are not
thought to be expressed exclusively on any particular cell type.
Na+/K+-ATPase is a crucial plasma membrane bound enzyme
that determines the cellular resting potential by pumping sodium
ions out from and potassium ions in to cells, against their
concentration gradients. Amongst other things, a stable resting
potential inhibits the opening of voltage dependant calcium
channels. In neurons, neurotransmitter binding causes a depolar-
isation of the membrane, thereby opening ion channels allowing
calcium influx and activation of several important secondary
functions. It is therefore perhaps unsurprising that mutations and
defects in both a2- and a3-chains of Na+/K+-ATPase have been
associated with neurodegenerative disorders [43]. Palladino et al
observed that mutations in the Drosophila a-subunit of Na+/K+-
ATPase resulted in severe neuronal damage and a marked
reduction in lifespan [44]. Previous work by the same group had
indicated that inhibition of the Na+/K+-ATPase caused spongi-
form vacuolation similar to that seen in TSE infections [45].
Furthermore, PrPC has been shown to interact either directly or
indirectly with Na+/K+-ATPase by a variety of techniques,
including affinity chromatography [42], cross linking in tissue
samples [9,26,42] and co-immunoprecipitation experiments [8].
Based on the above evidence, we reasoned that Na+/K+-
ATPase may represent a prion protein conversion cofactor and we
sourced Na+/K+-ATPase commercially to allow us to assess
whether it modulated misfolding in two prion protein misfolding
assays. Although commercially available Na+/K+-ATPase was
isolated from pigs and our in vitro misfolding assays use murine
recPrP, homology between porcine and murine Na+/K+-ATPase
a-subunit isoforms is typically greater than 99% and we
considered it unlikely that species differences would have a major
impact on our results. Firstly, we used a well characterised cell free
conversion assay (CFCA) [46], which uses SAF preparations as a
source of PrPSc to convert recPrP into a proteinase K-resistant
isoform. The newly formed PK resistant recPrP can be detected
against a background of PrPSc by the prior incorporation of an
antibody recognition epitope into recPrP, in this case the 3F4
monoclonal antibody epitope. The CFCA has previously been
shown to replicate many aspects of TSE disease including species
and polymorphism barriers [47]. The assay is also inhibited by
anti-TSE drugs [46] and we have recently shown that conversion
of recPrP in the assay can be enhanced by the inclusion of
subcellular fractions enriched for plasma membrane [39].
Figure 3(a) shows results of a typical CFCA experiment seeded
with ME7 scrapie and detected by SDS-PAGE and Western
blotting. The assay contains both positive and negative control
reactions as well as several reactions supplemented with increasing
concentrations of Na+/K+-ATPase. In the presence of SAF but the
absence of Na+/K+-ATPase, a PK resistant product is formed
from recPrP (Figure 3(a) lanes 1 & 2). In the absence of SAF, no
protease-resistant product is formed, even when Na+/K+-ATPase
is included (lanes 11–14). In the presence of both PrPSc and Na+/
K+-ATPase, the intensity of the band corresponding to protease-
resistant recPrP conversion product increases with increasing
amounts of Na+/K+-ATPase. We repeated the experiment
multiple times and averaged the conversion efficiencies of recPrP
in the presence of Na+/K+-ATPase, by setting the positive control
reaction to 100% conversion. Figure 3(b) shows, graphically, the
average conversion efficiencies as a function of Na+/K+-ATPase
concentration and demonstrates clearly that Na+/K+-ATPase
enhances production of protease resistant recPrP in our CFCA.
The number of replicate experiments performed for each
concentration of Na+/K+-ATPase is displayed on the bar chart.
One-sample t-tests demonstrate increases in reactions incorporat-
ing 0.2, 0.8, 3.2 and 6.4 mg/ml Na+/K+-ATPase relative to
control reactions are statistically significant, as indicated by
asterisks on Figure 3(b). Although conversion efficiencies in
reactions incorporating 0.4 and 1.6 mg/ml Na+/K+-ATPase were
not statistically significant, the underlying trend of the data is
towards increased conversion in reactions incorporating Na+/K+-
ATPase. Moreover, statistically significant conversion efficiencies
were measured at concentrations of Na+/K+-ATPase of only
0.2 mg/ml, which is ,3 fold less than the concentration of recPrP
in the assay in molar terms (see materials and methods for details),
suggesting that Na+/K+-ATPase is capable of enhancing conver-
sion even at sub-stoichiometric levels.
During commercial production, Na+/K+-ATPase is isolated by
sodium iodide extraction of microsome preparations and prepared
as a lyophilised powder in 90% sucrose. We assessed the effect of
the sucrose carrier on cell free conversion of recPrP (Figure S1)
and although calculated conversion efficiencies were variable,
partly because high concentrations of sucrose cause loading
problems for SDS-PAGE gels, the general trend of the data
indicates that sucrose has no effect on conversion efficiency of
recPrP in the CFCA. Thus, we concluded that Na+/K+-ATPase
specifically enhances conversion of recPrP and may act as a prion
protein conversion cofactor.
We also tested the effect of Na+/K+-ATPase on the kinetics of in
vitro fibrillisation of recombinant PrP, a misfolding pathway that is
promoted by partially-denaturing concentrations of guanidine
hydrochloride. Several recent findings have suggested that
fibrillisation is a competing pathway to disease-specific conversion
and results in structures that are of limited physiological relevance
[48,49]. Indeed, we have previously found that cellular factors
promoting disease-specific misfolding also inhibit in vitro chao-
trope-induced fibrillisation [6,39]. We fibrillised murine recombi-
nant PrP in the presence or absence of Na+/K+-ATPase,
monitoring the extent of fibrillisation by the increase in
fluorescence from thioflavin T (ThT), and typical results are
shown in Figure 4. Panel (a) shows fibrillisation of wildtype murine
recPrP alone. The lag time to onset of fibrillisation is ,200 min-
utes and the subsequent elongation of fibrils occurs rapidly. Panels
(b)–(d) show fibrillisation of recPrP in the presence of increasing
amounts of Na+/K+-ATPase. We found only a modest increase in
the lag time to fibrillisation when Na+/K+-ATPase was present
when compared to control reactions. In previous work, we have
found that dramatic changes in lag time can be achieved by subtle
variations in solution conditions, but the incorporation of Na+/K+-
ATPase altered lag times by only ,100 minutes. Conversely, we
found that the kinetics of the subsequent elongation phase was
dramatically delayed in the presence of higher concentrations of
Na+/K+-ATPase as compared to control reactions. It should be
noted that the concentrations of Na+/K+-ATPase used are around
100 fold less than the molar concentration of recPrP in the
fibrillisation assay indicating that inhibition occurs at exceptionally
low PrP:Na+/K+-ATPase stoichiometry. For control reactions
(panel (a)) it is possible to fit sigmoidal curves to the data, which
allows calculations of lag times and rates of elongation. However,
it was not possible accurately to fit sigmoidal curves to data
obtained from reactions in the presence of Na+/K+-ATPase
because the elongation phases are inhibited to such an extent,
hence statistical comparisons of the effect of Na+/K+-ATPase
cannot be made. We assessed the effect of sucrose, the carrier
included in Na+/K+-ATPase preparations, on fibrillisation of
recPrP and found that fibrillisation kinetics were not demonstrably
different to controls (Figure S2). Thus, we find that Na+/K+-
ATPase negatively impacts recombinant PrP fibrillisation pre-
dominately by inhibiting the elongation phase of fibrillisation, data
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which suggests that binding of recPrP to Na+/K+-ATPase may be
a key factor mediating prion misfolding.
Na+/K+-ATPase links prion protein function and
misfolding
Combined, our findings provide one of the first links between
normal PrPC function and TSE disease-specific misfolding of the
prion protein. The major function of PrPC has remained
enigmatic, despite evidence of roles in many biochemical
processes, including metal ion binding and transport [50],
protection against reactive oxygen species through an inherent
superoxide dismutase activity [51], signal transduction [52,53],
neuroprotection [54] and regulation of calcium homeostasis [55].
However, in the absence of PrPC, knockout mice develop
essentially normally [56] and the only major phenotypic
abnormality is a neuropathy associated with demyelination of
peripheral nerves, which manifests only late in life [57]. These
observations contribute towards the case for PrPC as a neuropro-
tective molecule that is important during times of acute stress, such
as exposure of cells to reactive oxygen species [58], withdrawal of
serum from cell cultures [59] or age of an individual [57].
Evidence to implicate PrPC as a ‘specific’ neuroprotective
molecule is limited [60], however, and available evidence points
instead to a function for PrPC in aiding the regulation of cellular
homeostatic mechanisms. PrPC may facilitate normal neuronal
processes and a regulatory association with Na+/K+-ATPase may
underlie this function, as previously suggested by Kleene et al. [26].
Under normal circumstances, Na+/K+-ATPase works at ,30% of
Figure 3. Na+/K+-ATPase enhances cell free conversion of recPrP. (A) Western blot of a typical cell free conversion assay seeded with ME7
fibrils in the presence (lanes 3–10) of Na+/K+-ATPase at increasing concentrations following protease treatment. Lanes 1 & 2 contain CFCA reactions in
the absence of Na+/K+-ATPase, both without and with protease digestion, and represent the reaction to which data are normalised. Lanes 11–14
contain negative control reactions without and with protease to demonstrate that recombinant PrP does not convert spontaneously in the absence
of PrPSc, even in the presence of Na+/K+-ATPase. (B) Bar chart showing conversion efficiencies of recombinant PrP as a function of the amount of Na+/
K+-ATPase added. Cell free conversion assays were repeated multiple times, as indicated, and percent conversion was normalised relative to control
reactions containing no additive, the efficiency of which was set to 100% and indicated by the dotted line. Error bars show 6 standard error of
conversion efficiency for each concentration point. Bars marked with an asterisk are significantly different from controls. Nominal Na+/K+-ATPase
concentrations are given based on weight of lyophilised powder and for details of the calculated Na+/K+-ATPase concentrations used see materials
and methods.
doi:10.1371/journal.pone.0026813.g003
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its peak pumping capacity. However, under certain conditions
such as during cellular stress, the Na+/K+-ATPase needs to
operate at a greater capacity since it maintains the electrical
gradient required to drive other cellular processes. This includes
maintaining neuronal calcium fluxes by the Na+/Ca2+ exchanger
[61] or astrocytic removal of glutamate following synaptic
transmissions [62]. Recent findings have also indicated a role for
the Na+/K+-ATPase in signal transduction that is not linked to its
enzymatic function [63,64]. Kleene et al found that the lack of
PrPC in knockout mice results in lower efficiencies of Na+/K+-
ATPase pumping without affecting resting membrane potential
[26]. This suggests that the loss of PrPC may preclude Na+/K+-
ATPase working at full capacity when it is needed - e.g. during
times of stress - resulting in many of the subtle defects in PrP-null
mice [65,66,67,68]. It is not yet known whether lack of PrP alters
signal transduction through Na+/K+-ATPase.
In addition to a putative function role for a complex involving
PrPC and Na+/K+-ATPase, the presence of Na+/K+-ATPase in
SAF preparations suggests that such a complex is important for
PrP misfolding in vivo. This is evidenced by our demonstrations
that Na+/K+-ATPase can modulate different misfolding pathways
of PrP. Various groups have shown interactions between Na+/K+-
ATPase and PrPC [8,9,42] and there have been several suggestions
that the two proteins associate to form a multiprotein complex
with additional partners. One such partner is suggested to be 29,39-
cyclic nucleotide 39-phosphodiesterase (CNP1) [69] and interest-
ingly this protein was identified in one of our SAF preparations
and was also detected in another below the level of confidence.
CNP1 is a membrane bound enzyme involved in the synthesis of
the myelin sheath [70] and it has been reported that CNP1 may
act as an anchor for tubulin [71]. Thus, the involvement of a PrP-
ATPase-CNP1 complex in prion protein function and misfolding
may explain a range of observations from our data and from that
of other studies in the field.
A key question to determine the role of Na+/K+-ATPase in PrP
misfolding in vivo is whether Na+/K+-ATPase knockout mice can
sustain a prion infection, but homozygous knockout of either a2-
or a3-chains result in lethality [72]. Hemizygous knockout mice
(a2 or a3) exhibit a range of behavioural and physiological
abnormalities [72] and, against this background, proving a direct
role for Na+/K+-ATPase in prion misfolding in vivo may be
challenging. Nevertheless, it is possible to develop a hypothetical
model in which, under normal conditions, PrPC participates in the
regulation of the activity of Na+/K+-ATPase allowing it to increase
activity on demand. During TSE disease, PrPC is lost as it is
converted to PrPSc, thereby reducing the functional PrPC available
and compromising Na+/K+-ATPase enzymatic or signalling
functions. In addition, Na+/K+-ATPase is sequestered from the
surface of neurons and/or astrocytes into the growing fibril and
this double loss of function, coupled with partial toxicity of
extracellular, fibrillar deposits, may be sufficient to initiate a
cascade of intracellular events that culminate in neuronal loss.
Figure 4. Fibrillisation of recPrP is inhibited by Na+/K+-ATPase at low stoichiometries. Murine recPrP was fibrillised in a buffer containing
2 M guandinium hydrochloride and different amounts of Na+/K+-ATPase. Reactions were performed in triplicate and fibrillisation was monitored by
the increase in ThT fluorescence over time. After subtraction of background fluorescence from control wells, the resulting data were normalised to
express the ThT fluorescence as a percentage of the maximum signal. (A) recPrP alone (B) final nominal concentration of 18 mg/ml Na+/K+-ATPase (C)
final nominal concentration of 35 mg/ml Na+/K+-ATPase (D) final nominal concentration of 70 mg/ml Na+/K+-ATPase. For details of the calculated
concentrations of Na+/K+-ATPase used see materials and methods.
doi:10.1371/journal.pone.0026813.g004
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Such a process could explain the requirement for PrPC for
neurotoxicity of oligomeric protein preparations [73] and there is
significant evidence pointing to a role for electrophysiological
disturbances in the toxicity of prion protein aggregates [74]. We
are certainly not the first to suggest a key role for the loss of Na+/
K+-ATPase function in TSE diseases [45,75,76] but our work is
the first to demonstrate that Na+/K+-ATPase is present in SAF
and that this protein can mediate misfolding of PrP.
The analysis of SAF from mouse scrapie strains by mass
spectrometry has highlighted various proteins as being associated
with PrPSc and raises intriguing questions over their potential roles
in PrP conversion. Our finding that one of the copurifying
proteins, Na+/K+-ATPase, enhances cell free conversion of
recombinant PrP, suggests that this protein, potentially in
association with other binding partners, may be integral to
facilitating PrP conversion in vivo.
Materials and Methods
Ethics Statement and generation of infected tissue
samples
All experimental protocols were approved by the ‘Institute for
Animal Health Neuropathogenesis Division Ethical Review
Process’ and experimentation was carried out under licences 14-
79-0560 and 14-92-3745 granted by the UK Home Office. All
experiments were performed accordance with the UK Home
Office Regulations (Animals (Scientific Procedures) Act 1986).
ME7, 22F and 79A scrapie strains were passaged in either C57bl/
6 or CV mice, both of which have the Prnpa genotype. All mice
were kept in contained conditions at The Roslin Institute mouse
facility. Mice were culled when clinical signs became apparent
according to approved clinical monitoring criteria, brains were
immediately removed, snap frozen in liquid nitrogen and stored at
280uC until used.
Purification of scrapie associated fibrils
Based on a method described by Hope et al. [27], SAF were
isolated from the brains of terminally TSE infected animals. A 5%
(w/v) homogenate was prepared from a pool of 4 mouse brains in
a buffer containing 10% (w/v) N-lauroylsarcosine, 0.1 M sodium
phosphate, pH 7.4. The homogenate was centrifuged at 22,000 g
for 30 minutes at 10uC, the pellet was discarded and the
supernatant centrifuged at 215,000 g for 150 minutes at 10uC.
The pellet was re-suspended in 3 ml H2O followed by incubation
at room temperature for 1 hour. To this, 9 ml of iodide solution
(0.9 M potassium iodide, 15 mM sodium phosphate, 9 mM
sodium thiosulphate, 1.5% (w/v) N-lauroylsarcosine, pH 8.5) was
added. The suspension was centrifuged at 285,000 g for
90 minutes at 10uC through a cushion of 20% (w/v) sucrose in
0.6 M potassium iodide, 10 mM sodium phosphate, 6 mM
sodium thiosulphate, 1% (w/v) N-lauroylsarcosine sodium salt,
pH 8.5. The resultant pellet was washed in H2O and centrifuged
at 13,000 g for 30 minutes at room temperature. The final SAF
pellet was re-suspended in H2O to approximately 1 mg/ml by
sonication, estimated based on a yield of 10 mg per mouse brain.
Densitometric analysis of semi-quantitative Western blots incor-
porating serial dilutions of recombinant murine PrP gave a more
accurate concentration and appropriate modifications were made
to give 1 mg/ml final concentration.
SDS-PAGE and Western blotting analysis of SAF
preparations
For Western blots, the following primary antibodies were used:
Na+/K+-ATPase pan a-chain, rabbit polyclonal (H-300, Santa
Cruz Biotechnology Inc), Na+/K+-ATPase a2-chain, rabbit
polyclonal (AB9094, Millipore), Na+/K+-ATPase a3-chain, goat
polyclonal (Y-13, Santa Cruz Biotechnology Inc), ApoE, rabbit
polyclonal (AMS Biotechnology), PrP, 8H4 and 3F4 mouse
monoclonal (TSE Resource Centre, The Roslin Institute). Protein
samples were separated by SDS-PAGE using 4–12% (w/v)
NuPAGE Bis-Tris gradient gels (Invitrogen). Silver nitrate staining
of SDS-PAGE gels was carried out according to the Plus One
silver staining protocol (GE Healthcare). For Western blotting, gels
were semi-dry blotted onto Immobilon-P PVDF membrane
(Whatman). The membrane was probed with the appropriate
primary antibody, and secondary antibody binding was detected
by ECL Western blotting detection reagent (GE Healthcare). The
membrane was dried and exposed to hyperfilm-MP (GE
Healthcare), which was developed by a Compact Xograph X4
(Xograph Imaging Systems).
Shotgun Liquid chromatography-tandem mass
spectrometry (LC-MS/MS) of scrapie associated fibrils
SAF preparations were reduced and carboxymethylated in
6 M guanidine hydrochloride, 100 mM ammonium bicarbon-
ate (pH 8.5) by use of 40 mM dithiothreitol and 200 mM
iodoacetamide respectively, followed by precipitation at 220uC
for 12 hours in 20 volumes of ethanol. The resultant pellet was
resuspended in 4 M urea, 100 mM ammonium bicarbonate
(pH 8.5) prior to tryptic digestion (1:20 enzyme:substrate ratio
by weight) at 37uC for 8 hours. Tryptic peptides were
concentrated using a 180 mm620 mm, 5 mm Symmetry C18
trap (Waters) for 3 min at 10 ml/min, and resolved on a
1.7 mm, 100 mm6100 mm, BEH 130 C18 column (Waters) at
400 nl/min that was attached to a nano Acquity UPLC
(Waters). Peptides were eluted over a linear gradient of 0–
50% (v/v) acetonitrile, 0.1% (v/v) formic acid for 30 minutes
with a flow rate of 400 nl/min. To complete the elution, the
column was washed with 85% (v/v) acetonitrile, 0.1% (v/v)
formic acid for 7 minutes. Ionised peptides were analysed by a
quadrupole time of flight (Q-ToF) Premier mass spectrometer
(Waters) in data-dependent acquisition mode where a MS
survey scan was used to automatically select multicharged
peptides for further MS/MS fragmentation. From each survey
scan up to three peptides were selected for fragmentation. MS/
MS collision energy was dependent on precursor ion mass and
charge state. A reference spectrum was collected at every
30 seconds from Glu-fibrinopeptide B (785.8426 m/z), intro-
duced via a reference sprayer. Raw MS/MS spectra were
processed using ProteinLynx Global Server (Waters) and were
searched against the IPI murine protein database by use of the
Mascot search algorithm. Search parameters are given in
Supplementary Materials and Methods.
Cell free conversion assays
Details of our cell free conversion assay have previously been
published [46]. Briefly, recombinant PrP incorporating a 3F4
antibody recognition epitope was produced by expression in
bacteria. After bacterial lysis and inclusion body solubilisation,
the protein was purified by sequential chromatographic steps of
nickel ion affinity and cation exchange chromatography. Protein
containing fractions were oxidized overnight, in the presence of
copper ions, to form the single disulfide bond, and were
extensively dialysed against 50 mM sodium acetate, pH 5.5.
SAF were prepared as above from ME7 infected mouse brains
and were mixed at a ratio of 5:1 (SAF:recPrP) with the 3F4-
tagged recPrP substrate in an assay buffer supplemented with
different concentrations of Na+/K+-ATPase. The final concen-
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trations of PrPSc and recPrP used were 50 mg/ml and 10 mg/ml
respectively. The mixture was incubated at 37uC for 24 hours
and was subsequently treated with proteinase K, after prior
removal of an aliquot equal to 1/10th of the reaction mixture for
use as a -PK control. All samples were separated by SDS-PAGE
and PK-resistant recombinant PrP was detected by Western
blotting using the 3F4 antibody, which does not detect wildtype
murine PrP. Western blots were scanned by use of an
ImageScanner III (GE Healthcare) and protein bands quantified
by densitometric methods using ImageQuant software (GE
Healthcare). We defined the control reaction, without Na+/K+-
ATPase, as being 100% conversion and normalised data relative
to this reaction.
Fibrillisation of murine recombinant PrP in the presence
of Na+/K+-ATPase
The methods for production of murine recombinant PrP and
fibrillisation of this protein have previously been published [39]
and follow those previously described by the group of Baskakov
[77,78]. Briefly, recombinant PrP was expressed by bacteria and
protein was purified from inclusions bodies by immobilized metal
ion affinity chromatography, size exclusion chromatography and
reversed phase chromatography followed by lyophilisation.
Protein, at a final concentration of 5 mM, was fibrillised in a
guanidinium hydrochloride containing buffer (2 M guanidine
HCl, 10 mM thiourea, 120 mg/ml recPrP, 50 mM 2-(N-morpho-
lino)ethanesulfonic acid (MES) pH 6.0, 10 mM ThT) by shaking at
900 rpm in a 96 well plate. The extent of fibrillisation was
monitored in real time by the increase in ThT fluorescence by use
of a Fluoroskan Ascent (Thermo Scientific) plate reader with
excitation at 444 nm and emission at 485 nm. Readings were
taken every 5 minutes and the fibrillisation reaction was
monitored for 24 hours.
Addition of Na+/K+-ATPase to misfolding assays
Na+/K+-ATPase was purchased from Sigma. To determine the
effect of Na+/K+-ATPase on cell free conversion of recPrP,
doubling dilutions of Na+/K+-ATPase solution in conversion assay
buffer were prepared from a starting concentration of 12.8 mg/
ml. These were added 1:1 to cell free conversion assays to yield
nominal concentrations of 6.4 mg/ml–0.1 mg/ml Na+/K+-
ATPase. However, Na+/K+-ATPase as purchased was only 10%
by weight of the lyophilised powder (the balance was sucrose)
hence effective concentrations of Na+/K+-ATPase were in the
range 0.64–0.01 mg/ml. Assuming a combined molecular weight
of the assembled Na+/K+-ATPase complex of ,154 kDa (a-chain
,111.5 kDa, b-chain ,35 kDa, c-chain ,7.5 kDa), the final
concentrations of Na+/K+-ATPase in CFCA ranged from 4 mM to
30 nM. By comparison, recPrP concentration in each CFCA was
430 nM. All cell free conversion assays were repeated at least 3
times.
To determine the affect of Na+/K+-ATPase on PrP fibrillisa-
tion, three different concentrations of enzyme were added to 3
replicate wells of a 96 well plate containing recombinant PrP in
fibrillisation buffer. Using the above figures for nominal Na+/
K+-ATPase concentrations and molecular weight, the final
concentrations of Na+/K+-ATPase in fibrillisation reactions
equated to 45.5, 22.5 and 11.5 nM. By comparison, recPrP
concentration was ,5 mM. The entire experiment was repeated
three times to yield 9 independent replicates per ATPase
concentration.
Supporting Information
Figure S1 Sucrose does not enhance cell free conversion
of murine recPrP. Cell free conversion assays used a SAF
preparation from ME7 infected mice as seed and murine
recombinant PrP and were performed according to the materials
and methods section. Sucrose was added to the final concentra-
tions shown. The Western blot was imaged and densitometry was
used to calculate the percentage conversion of recombinant PrP
for each reaction. The percent conversion of the positive control
reaction was set to 100% and sucrose-containing reactions were
normalised accordingly.
(DOC)
Figure S2 Sucrose has no effect on in vitro fibrillisation
of murine recPrP. Thioflavin T fluorescent profiles during
fibrillisation of murine recombinant PrP, in triplicate, in the
presence of (A) no additive (B) 50 mg/ml Sucrose (C) 200 mg/ml
sucrose (D) 800 mg/ml sucrose. After subtraction of background
fluorescence, thioflavin t fluorescence was normalised to 0–100%
for each reaction.
(DOC)
Table S1 Full, compiled list of proteins identified in SAF
preparations from infected mouse brains. SAF were
purified from the brains of mice infected with ME7, 22F or 79A
strains of mouse-passaged scrapie. Duplicate preparations were
made and the 6 samples were reduced and alkylated in 6 M
guanidine hydrochloride prior to tryptic digestion. Tryptic
peptides were separated and detected by online LC-MS/MS
and the data searched against the IPI murine database by use of
the Mascot search algorithm. Proteins are listed in the table if they
were identified conclusively in at least one SAF preparation.
Protein hits were deemed to be conclusively identified if they were
above the level of significance (as determined by Mascot scores)
and more than one peptide matched to the sequence. Those
proteins in upper rows and italicised were found in control
preparations from uninfected brains either in the current study or
in Moore et al. nd – not detected. dbcl – protein detected but below
the level of confidence because only a single peptide was matched.
a – due to extensive sequence homology between different chains
of these proteins it is not possible to tell whether only a single
isoform or multiple isoforms are present.
(DOC)
Supplementary Mascot Searches S1 Composite file of
results from Mascot searches on LC-MS/MS data. The
file is composed of Mascot single searches of SAF derived from
uninfected mice and PrP2/2 as well as SAF derived from 2
replicate preparations each of wild type mice infected with ME7,
22F and 79A strains of mouse passaged scrapie.
(PDF)
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